natgillin/translations-raw huggingface dataset:
In healthy young cats aged 7–8 months, oral robenacoxib administered at high overdoses (4, 12 or 20 mg/kg/day for 6 weeks) did not produce any signs of toxicity, including no evidence of any gastrointestinal, kidney or liver toxicity and no effect on bleeding time.
U zdravih mladih mačaka u dobi od 7 - 8 mjeseci, robenakoksib peroralno primijenjen, u značajno prekomjernim dozama (4, 12 ili 20 mg/kg/dnevno tijekom 6 tjedana) nije pokazao znakove toksičnosti uključujući i nepostojanje dokaza o bilo kakvoj gastrointestinalnoj, bubrežnoj ili jetrenoj toksičnosti, te nije imao utjecaj na vrijeme krvarenja.
In healthy young cats aged 7–8 months, oral robenacoxib administered at high overdoses (4, 12 or 20 mg/kg/day for 6 weeks) did not produce any signs of toxicity, including no evidence of any gastrointestinal, kidney or liver toxicity and no effect on bleeding time.
U zdravih mladih mačaka u dobi od 7 - 8 mjeseci, robenakoksib primijenjen peroralno u značajno prekomjernim dozama (4, 12 ili 20 mg/kg/dnevno tijekom 6 tjedana) nije pokazao znakove toksičnosti uključujući i nepostojanje dokaza o bilo kakvoj gastrointestinalnoj, bubrežnoj ili jetrenoj toksičnosti, te nije imao utjecaj na vrijeme krvarenja.
In healthy young dogs aged 5–6 months, oral robenacoxib administered at high overdoses (4, 6 or 10 mg/kg/day for 6 months) did not produce any signs of toxicity, including no evidence of any gastrointestinal, kidney or liver toxicity and no effect on bleeding time.
U zdravih mladih pasa u dobi od 5 - 6 mjeseci, robenakoksib primijenjen peroralno u značajno prekomjernim dozama (4, 6 ili 10 mg/kg/dnevno tijekom 6 mjeseci) nije pokazao znakove toksičnosti uključujući i nepostojanje dokaza o bilo kakvoj gastrointestinalnoj, bubrežnoj ili jetrenoj toksičnosti te nije imao utjecaj na vrijeme krvarenja.
In healthy young dogs aged 6 months, once daily subcutaneous administration of robenacoxib at doses of 2 (recommended therapeutic dose; RTD), 6 (3 times RTD), and 20 mg/kg (10 times RTD) for 9 administrations over a 5 week period (3 cycles of 3 consecutive once daily injections) did not produce any signs of toxicity, including gastrointestinal, kidney or liver toxicity and had no effect on bleeding time.
U zdravih mladih pasa u dobi od 6 mjeseci, subkutana primjena robenakoksiba jednom dnevno pri dozama od 2 (preporučena terapijska doza; RTD), 6 (tri puta RTD) i 20 mg/kg (10 puta RTD) za 9 primjena tijekom razdoblja od pet tjedana (3 ciklusa od 3 uzastopne injekcije jednom dnevno) nije uzrokovala nikakve znakove toksičnosti uključujući i gastrointestinalnu toksičnost, toksičnost bubrega ili jetre i nije imala utjecaja na vrijeme krvarenja.
In heavily pretreated patients the use of Telzir in combination with low dose ritonavir has not been sufficiently studied.
Primjena kombinacije lijeka Telzir i niske doze ritonavira nije dovoljno ispitana kod bolesnika koji su prethodno primali snažno antiretrovirusno liječenje.
In hepatic transplant patients initiated on CellCept and tacrolimus, the AUC and Cmax of MPA, the active metabolite of CellCept, were not significantly affected by co-administration with tacrolimus.
Kod bolesnika s presađenom jetrom kod kojih je započeto liječenje lijekom CellCept i takrolimusom, istodobna primjena takrolimusa nije značajno utjecala na AUC i Cmax aktivnog metabolita lijeka CellCept, MPA .
In hidradenitis suppurativa, 59% of patients receiving Humira in one main study and 42% of patients in another achieved at least a 50% reduction in abscesses and nodules after 12 weeks, without any increase in abscess count or fistulas.
U slučaju hidradenitisa suppurative, u 59 % bolesnika koji su primali lijek Humira u glavnom ispitivanju i u 42 % bolesnika u drugom ispitivanju nakon 12 tjedana došlo je do najmanje 50 %-tnog smanjenja čvorića i kvržica, bez povećanja apscesa ili fistula.
In hip fracture patients, associated with their increased age, fondaparinux steady state plasma concentrations are: Cmax (mg/l) - 0.50 (32%), Cmin (mg/l) - 0.19 (58%).
U bolesnika s frakturom kuka povezanom s njihovom starijom životnom dobi, koncentracije fondaparinuksa u plazmi u stanju dinamičke ravnoteže su: Cmax (mg/l) – 0,50 (32%), Cmin (mg/l) – 0,19 (58%).
In HIV infected patients co-infected with HBV, clinical and laboratory evidence of hepatitis have occurred after discontinuation of tenofovir disoproxil fumarate (see section 4.4).
U pacijenata s HIV-om koji su istovremeno imali infekciju HBV-om, nakon prekida liječenja tenofovirdizoproksilfumaratom hepatitis se mogao klinički i laboratorijski dokazati (vidjeti dio 4.4).
In HIV infected patients co-infected with HBV, clinical and laboratory evidence of hepatitis have occurred after discontinuation of treatment (see section 4.4).
U pacijenata s HIV-om koji su istovremeno imali infekciju HBV-om, nakon prekida liječenja hepatitis se mogao klinički i laboratorijski dokazati (vidjeti dio 4.4).
In HIV infected patients co-infected with HBV, clinical and laboratory evidence of hepatitis have occurred after discontinuation of treatment (see section 4.4).
U pacijenata s HIV-om koji su istovremeno imali infekciju HBV-om, nakon prekida liječenja pojavili su se klinički i laboratorijski dokazi hepatitisa (vidjeti dio 4.4).
In HIV infected patients treated with CART, including with emtricitabine, immune reactivation syndrome has been reported.
U bolesnika zaraţenih HIV-om koji se liječe CART-om, uključujući emtricitabin, zabiljeţen je sindrom imunološke reaktivacije.
In HIV infected patients treated with CART, including with emtricitabine, immune reactivation syndrome has been reported.
U bolesnika zaraženih HIV-om koji se liječe CART-om, uključujući emtricitabin, zabilježen je sindrom imunološke reaktivacije.
In HIV infected patients with severe immune deficiency at the time of initiation of CART, an inflammatory reaction to asymptomatic or residual opportunistic infections may arise.
U bolesnika zaraţenih HIV-om s teškom imunodeficijencijom u vrijeme početka CART-a moţe nastati upalna reakcija na asimptomatske ili rezidualne oportunističke infekcije.
In HIV infected patients with severe immune deficiency at the time of initiation of CART, an inflammatory reaction to asymptomatic or residual opportunistic infections may arise.
U pacijenata inficiranih HIV-om s teškom imunodeficijencijom u vrijeme uvođenja liječenja CART- om mogu nastati upalna reakcija na asimptomatske ili rezidualne oportunističke infekcije.
In HIV infected patients with severe immune deficiency at the time of institution of CART, an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms.
U bolesnika zaraţenih HIV-om s teškom imunodeficijencijom u vrijeme uvoĎenja CART-a moţe doći do upalne reakcije na asimptomatske ili rezidualne oportunističke patogene, koja moţe uzrokovati teška klinička stanja ili pogoršanje simptoma.
In HIV infected patients with severe immune deficiency at the time of institution of CART, an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms.
U bolesnika zaraženih HIV-om s teškom imunodeficijencijom u vrijeme uvođenja CART može doći do upalne reakcije na asimptomatske ili rezidualne oportunističke patogene, koja može uzrokovati teška klinička stanja ili pogoršanje simptoma.
In HIV infected patients with severe immune deficiency at the time of institution of CART, an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms.
U pacijenata inficiranih HIV-om s teškom imunodeficijencijom u vrijeme uvoĎenja CART-a može doći do upalne reakcije na asimptomatske ili rezidualne oportunističke patogene, koja može uzrokovati teška klinička stanja ili pogoršanje simptoma.
In HIV infected patients with severe immune deficiency at the time of institution of CART, an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms.
U pacijenata inficiranih HIV-om s teškom imunodeficijencijom u vrijeme uvođenja CART može doći do upalne reakcije na asimptomatske ili rezidualne oportunističke patogene, koja može uzrokovati teška klinička stanja ili pogoršanje simptoma.
In HIV infected patients with severe immune deficiency at the time of institution of CART, an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms.
U pacijenata inficiranih HIV-om s teškom imunodeficijencijom u vrijeme uvođenja CART-a može doći do upalne reakcije na asimptomatske ili rezidualne oportunističke patogene koja može uzrokovati ozbiljna klinička stanja ili pogoršanje simptoma.
In HIV infected patients, in a 144-week controlled clinical study that compared tenofovir disoproxil fumarate with stavudine in combination with lamivudine and efavirenz in antiretroviral-naïve adult patients, small decreases in bone mineral density (BMD) of the hip and spine were observed in both treatment groups.
U 144-tjednom kontroliranom kliničkom ispitivanju u pacijenata inficiranih HIV-om u kojemu je uspoređivan tenofovirdizoproksilfumarat sa stavudinom u kombinaciji s lamivudinom i efavirenzom u odraslih pacijenata koji prethodno nisu bili liječeni antiretrovirusnim lijekovima, u obje su liječene skupine zapažena mala smanjenja mineralne gustoće (BMD) kosti kuka i kralježnice.
In HIV infected patients, peak efavirenz plasma concentrations were attained by 5 hours and steady-state concentrations reached in 6 to 7 days.
U pacijenata inficiranih HIV-om najviše koncentracije efavirenza u plazmi postignute su za 5 sati, a koncentracija u stanju dinamičke ravnoteže za 6 do 7 dana.
In HIV infection, it blocks the activity of reverse transcriptase, an enzyme produced by HIV that allows it to infect cells and make more viruses.
U slučaju infekcije HIV-om inhibira djelovanje povratne transkriptaze, enzima koji stvara HIV, a koji virusu omogućuje infekciju stanica u tijelu i stvaranje većeg broja virusa.
in HIV patients enlargement of the spleen (splenomegaly)
kod HIV bolesnika uvećanje slezene (splenomegalija)
in HIV patients enlargement of the spleen (splenomegaly)
u bolesnika s HIV infekcijom povećanje slezene (splenomegalija)
in HIV patients enlargement of the spleen (splenomegaly)
u bolesnika s HIV-om povećanje slezene (splenomegalija)
in HIV patients pain in your muscles or bones (musculoskeletal pain)
kod HIV bolesnika bol u mišićima ili kostima (mišićno-koštana bol)
in HIV patients pain in your muscles or bones (musculoskeletal pain)
u bolesnika s HIV infekcijom bol u mišićima ili kostima (mišićno-koštana bol)
in HIV patients pain in your muscles or bones (musculoskeletal pain)
u bolesnika s HIV-om bolovi u mišićima ili kostima (mišićno-koštani bolovi)
in HIV patients severe pain in the bones, chest, gut or joints (sickle cell crisis)
kod bolesnika s HIV-om teška bol u kostima, prsima, želudcu ili zglobovima (kriza srpastih stanica)
in HIV patients severe pain in the bones, chest, gut or joints (sickle cell crisis)
u bolesnika s HIV infekcijom teška bol u kostima, prsištu, crijevima ili zglobovima (kriza srpastih stanica)
in HIV patients severe pain in the bones, chest, gut or joints (sickle cell crisis)
u bolesnika s HIV-om teški bolovi u kostima, prsištu, crijevu ili zglobovima (kriza srpastih stanica)
In HIV-1 infected children, the BMD Z-scores observed in subjects who switched to tenofovir disoproxil fumarate were lower than those observed in subjects who remained on their stavudine- or zidovudine-containing regimen (see sections 4.4 and 5.1).
U djece zaražene virusom HIV-1, Z-rezultati BMD-a opaženi u ispitanika koji su prešli na tenofovirdizoproksilfumarat bili su niži od onih opaženih u ispitanika koji su ostali na svom režimu liječenja stavudinom ili zidovudinom (vidjeti dijelove 4.4 i 5.1).
In HIV-1 infected patients with renal risk factors, the co-administration of tenofovir disoproxil fumarate with a boosted protease inhibitor should be carefully evaluated.
U pacijenata zaraženih virusom HIV-1 s bubrežnim čimbenicima rizika potrebno je pažljivo procijeniti istovremenu primjenu tenofovirdizoproksilfumarata s pojačanim inhibitorom proteaze.
In HIV-1 infected patients with renal risk factors, the co-administration of tenofovir disoproxil with a boosted protease inhibitor should be carefully evaluated.
U bolesnika zaraženih virusom HIV-1 s bubrežnim čimbenicima rizika treba pažljivo procijeniti istodobnu primjenu tenofovirdizoproksila s pojačanim inhibitorom proteaze.
In HIV-HCV co-infected patients, the clinical adverse reaction profiles reported for Pegasys, alone or in combination with ribavirin, were similar to those observed in HCV mono-infected patients For
Prijavljeni profili kliničkih nuspojava za Pegasys, sam ili u kombinaciji s ribavirinom, u bolesnika istodobno zaraženih HIV-om i HCV-om slični su profilima zabilježenima u bolesnika zaraženih samo HCV-om.
In HIV-infected adult patients (n=33, combined studies), the mean half-life within a dosing interval for atazanavir was
U odraslih bolesnika s HIV infekcijom (n=33, kombinirana ispitivanja), srednji poluvijek unutar intervala doziranja atazanavira iznosio je
In HIV-infected adults, adding Viread to existing treatment resulted in a fall in viral load of around 75% after four and after 24 weeks, compared with a small rise or fall in viral load of around 5% in the patients taking placebo.
U odraslih osoba zaraženih HIV-om, dodavanje lijeka Viread postojećoj terapiji rezultiralo je smanjivanjem opterećenja virusa za otprilike 75% nakon četiri tjedna i nakon 24 tjedana, u usporedbi s povećanjem ili smanjenjem opterećenja virusom za otprilike 5% u bolesnika koji su uzimali placebo.
In HIV-infected patients with atazanavir/ritonavir at an increased dose of 400/100 mg once daily
Primjena atazanavira/ritonavira u povišenoj dozi od 400/100 mg jedanput na dan u bolesnika zaraženih HIV-om
In HIV-infected patients with atazanavir/ritonavir at the recommended dose 300/100 mg once daily
jedanput na dan u bolesnika zaraženih HIV-om
In HIV-infected patients with atazanavir/ritonavir at the recommended dose of 300/100 mg once daily
Primjena atazanavira/ritonavira u preporučenoj dozi od 300/100 mg jedanput na dan u bolesnika zaraženih HIV-om
In HIV-infected patients with mild to moderate hepatic impairment, an increase of approximately 30% in lopinavir exposure has been observed but is not expected to be of clinical relevance (see section 5.2).
U bolesnika zaraženih HIV-om, s blagim do umjerenim oštećenjem funkcije jetre, uočena je 30% veća izloženost lopinaviru, ali ne očekuje se da bi to bilo klinički značajno (vidjeti dio 5.2).
In HIV-infected patients with severe immune deficiency at the time of initiation of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise.
Kod bolesnika zaraženih HIV-om s teškom imunodeficijencijom u trenutku započinjanja kombinirane antiretrovirusne terapija (CART) može se pojaviti upalna reakcija na asimptomatske ili rezidualne oportunističke reakcije.
In HIV-infected patients with severe immune deficiency at the time of initiation of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise.
U bolesnika inficiranih HIV-om s teškom imunodeficijencijom u vrijeme početka kombinirane antiretrovirusne terapije (CART) može doći do pojave upalne reakcije do asimptomatske ili rezidualne oportunističke infekcije.
In HIV-infected patients with severe immune deficiency at the time of institution of combination anti- retroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms.
U bolesnika inficiranih virusom HIV-a s teškim imunološkim deficitom u trenutku uvođenja kombinirane antiretrovirusne terapije može se razviti upalna reakcija na asimptomatske ili rezidualne oportunističke patogene te uzrokovati ozbiljna klinička stanja ili pogoršanje simptoma.
In HIV-infected patients,total clearance of stavudine is 594±164 ml/min, and renal clearance is 237±98 ml/min.
Ukupni klirens stavudina u bolesnika inficiranih HIV-om iznosi 594±164 ml/min, a bubrežni klirens 237±98 ml/min.
In HIV–infected paediatric patients, the pharmacokinetic parameters of indinavir in apple sauce were: AUC0–8hr of 26,980 nM*h; peak plasma concentration of 13,711 nM; and plasma concentration at 8 hours post dose of 146 nM.
U pedijatrijskih bolesnika zaraženih HIV-om farmakokinetički parametri indinavira u jabučnom soku bili su: AUC0–8h = 26 980 nM*h; vršna koncentracija u plazmi = 13 711 nM; koncentracija u plazmi 8 sati nakon primjene doze = 146 nM.
In HL, Adcetris has been studied in one main study in 102 patients with CD30-positive HL, who had previously received an autologous stem cell transplant and whose cancer had come back or had not responded to previous treatment.
U pogledu HL-a, lijek Adcetris ispitivan je u jednom glavnom ispitivanju kojim je obuhvaćeno 102 bolesnika oboljelih od HL-a s pozitivnim CD30 koji su prethodno bili podvrgnuti transplantaciji autolognih matičnih stanica i u kojih se rak ponovno javio ili u kojih nije bilo pozitivnog odgovora na prethodno liječenje.
In homozygous familial hypercholesterolaemia, Repatha was studied in 2 main studies involving 155 patients, which included 14 children older than 12 years.
U slučaju homozigotne obiteljske hiperkolesterolemije, lijek Repatha ispitan je u 2 glavna ispitivanja kojim je obuhvaćeno 155 bolesnika, od kojih su 14-toro bila djeca starija od 12 godina.
In horses given the granules in sachet and oral suspension, slight urticaria (itchy rash) and diarrhoea were observed in clinical trials.
U kliničkim ispitivanjima uočena je blaga urtikarija (svrbljivi osip) proljev kod konja koji su primili granule u vrećici i oralnu suspenziju.
In horses with RAO, the immune system (the body’s natural defences) over-reacts to triggering substances (antigens) that are present in dust that the horse breathes in.
U konja oboljelih od RAO-a, imunosni sustav (prirodna obrana tijela) prekomjerno reagira na aktivirajuće tvari (antigene) koje su prisutne u prašini koju konji udišu.
In horses, a transient swelling at the injection site can occur but resolves without intervention.
Kod konja se može pojaviti prolazno oticanje na mjestu uboda, ali nestaje bez intervencije.
In horses, after intravenous injection meloxicam is eliminated with a terminal half-life of 8.5 hours.
Kod konja, nakon intravenske injekcije, terminalni poluživot izlučivanja meloksikama iznosi 8,5 sati.
In horses, anaphylactoid (allergic) reactions can occur and should be treated according to the signs presented.
U konja su moguće anafilaktičke (alergijske) reakcije koje treba simptomatski liječiti.
In horses, Inflacam is used for the relief of pain associated with colic (abdominal pain) and for the alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders (disorders affecting the muscles and bones).
Inflacam se primjenjuje u konja za ublažavanje bolova povezanih s kolikama (abdominalna bol) te za ublažavanje upale i olakšavanje bola u akutnim i kroničnim mišićno-koštanim poremećajima.
In horses, Metacam is used for the relief of pain associated with colic (abdominal pain) and for the alleviation of inflammation and relief of pain in both acute and chronic (long-term) musculo-skeletal disorders (disorders affecting the muscles and bones).
Metacam se koristi kod konja za ublažavanje boli povezane s kolikama (abdominalna bol) te za uklanjanje upale i ublažavanje boli u slučaju akutnih i kroničnih (dugotrajnih) mišićnokoštanih poremećaja (poremećaji koji zahvaćaju mišiće i kosti).
In horses, Rheumocam is used for the relief of pain associated with colic (abdominal pain) and for the alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders (disorders affecting the muscles and bones).
Rheumocam se koristi kod konja za ublažavanje boli povezane s kolikama (abdominalna bol) te za uklanjanje upale i ublažavanje boli u slučaju akutnih i kroničnih mišićnokoštanih poremećaja (poremećaji koji zahvaćaju mišiće i kosti).
In horses, transient swellings at the injection site can occur but resolves without intervention.
U konja, moguće je pojavljivanje prolaznog oticanja na mjestu ubrizgavanja koje će se povući bez intervencije.
In households of influenza-infected index cases, there was a reduction in the incidence of influenza from 26 % (23 / 89) in the group not receiving prevention to 11 % (9 / 84) in the group receiving prevention (58.5 % reduction [95 % CI 15.6 – 79.6; p = 0.0114]).
U kućanstvima u kojima su postojali indeks slučajevi zaraženi gripom došlo je do smanjenja incidencije gripe: od 26 % (23/89) u skupini u kojoj nije provedena prevencija, na 11 % (9/84) u skupini u kojoj je prevencija provedena (smanjenje od 58,5 % [95 % CI 15,6 – 79,6; p = 0,0114]).
In households of influenza-infected index cases, there was a reduction in the incidence of influenza from 26 % (23/89) in the group not receiving prevention to 11 % (9/84) in the group receiving prevention (58.5 % reduction [95 % CI 15.6 – 79.6; p = 0.0114]).
U kućanstvima u kojima su postojali indeks slučajevi zaraženi gripom došlo je do smanjenja incidencije gripe: od 26 % (23/89) u skupini u kojoj nije provedena prevencija, na 11 % (9/84) u skupini u kojoj je prevencija provedena (smanjenje od 58,5 % [95 % CI 15,6 – 79,6; p = 0,0114]).
In human clinical studies, a 10 mg oral dose of tenofovir alafenamide in Genvoya resulted in tenofovir diphosphate concentrations > 4-fold higher in PBMCs and > 90% lower concentrations of tenofovir in plasma as compared to a 245 mg oral dose of tenofovir disoproxil (as fumarate) in E/C/F/TDF.
U kliničkim ispitivanjima u ljudi, peroralna doza od 10 mg tenofoviralafenamida u lijeku Genvoya rezultira koncentracijama tenofovirdifosfata > 4 puta većima u PBMC-ovima i > 90% manjim koncentracijama tenofovira u plazmi u usporedbi s peroralnom dozom tenofovirdizoproksila (u obliku fumarata) od 245 mg u E/C/T/TDF.
In human pre-term labour, atosiban at the recommended dosage antagonises uterine contractions and induces uterine quiescence.
U slučaju prijetećeg prijevremenog poroda u žena, atosiban u preporučenoj dozi antagonizira kontrakcije maternice i inducira smirivanje maternice.
In human pre-term labour, atosiban at the recommended dosage antagonises uterine contractions and induces uterine quiescence.
U slučaju prijevremenih trudova u žena atosiban u preporučenoj dozi antagonizira kontrakcije maternice i inducira smirivanje maternice.
In human pre-term labour, atosiban at the recommended dosage antagonises uterine contractions and induces uterine quiescence.
U slučaju prijevremenog poroda u žena, atosiban u preporučenoj dozi antagonizira kontrakcije maternice i inducira smirivanje maternice.
In human serum the main metabolite is N-demethyltoremifene with mean half-life of 11 (range 4 - 20) days.
U ljudskom serumu glavni metabolit je N-demetiltoremifen s prosječnim poluvijekom od 11 (4 – 20 dana) dana.
In human subjects, hepatic enzyme induction by phenobarbital has led to an increase in total plasma clearance (approximately 25%) following intravenous administration of granisetron.
U ljudskim ispitanicima, indukcija jetrenih enzima fenobarbitalom nakon intravenske primjene granisetrona dovela je do porasta ukupnog klirensa iz plazme (za otprilike 25%).
In human washed blood cells also evidence of hemolysis was found with non-commercial formulations at fosaprepitant concentrations of 2.3 mg/ml and higher, although tests in human whole blood were negative.
Hemoliza je također utvrđena u ljudskim ispranim krvnim stanicama nakon primjene fosaprepitanta u oblicima koji nisu namijenjeni tržištu, i to pri koncentraciji od 2,3 mg/ml naviše, ali su testovi s punom krvlju bili negativni.